Sandbox VR Leans Into Franchise; 60% Deal Growth and Plans for 280 New Franchise Locations to Come
3.9.2024 16:00:00 EEST | Business Wire | Press release
Sandbox VR, the world's premier destination for premium location-based virtual reality experiences, is announcing significant growth milestones of its franchise program. The company saw 60% growth in franchise deals in Q2 with plans to open 280 new franchise locations in the next four years. This announcement comes on the heels of opening their 50th store on August 15. Located on the Gold Coast, the new location is the first Sandbox VR in Australia, expanding its global presence to four continents and nine countries.
Since opening its first store in Hong Kong in 2017, Sandbox VR has rapidly grown its global footprint with thriving corporate-owned locations and a robust franchising program. Today, its global locations see over 100k players monthly. In 2023, the company topped 1.2M tickets sold and has seen a 33% year-over-year increase in 2024 ticket sales. Sandbox VR’s corporate locations—37 in total—hit a revenue milestone with an average store topping $1.9M annually.
Sandbox VR's franchise program launched in 2019 for international markets and opened up for US territories in April of this year. In those four months, 33% of available Sandbox VR US franchise territories have been claimed by new and existing franchise partners. Franchising has been instrumental in making Sandbox VR the fastest growing location-based VR startup globally, and this US momentum signals continued rapid growth. Limited opportunities for prime locations and territory exclusivity are still available in the US.
“When I started building Sandbox VR, I set out to build the future of entertainment. I never would have succeeded without the right team of people helping me build the world's most immersive experiences using bleeding edge virtual reality technology,” said Steve Zhao, CEO and founder of Sandbox VR. “As we set our sights on expanding globally, we know it’s critical to work with the right partners. We are thrilled to announce the 50th Sandbox VR location in collaboration with our franchise partners, Bao Phung and Keith Le, and look forward to working with passionate franchise partners from around the globe to open hundreds more in the next four years.”
“We considered a different location-based virtual reality company when it came to exploring our franchise opportunities but ultimately determined that we wanted to partner with Sandbox VR, the leader in the category,” said Bao Phung, Owner of Sandbox VR Gold Coast. “Partnering with Sandbox VR was the most advantageous and strategic decision for our business, allowing us to introduce Australia to immersive games you can’t play anywhere else on the world’s most immersive full-body VR platform. The Gold Coast, which attracts 13 million visitors annually, is the natural choice for our first location. We look forward to introducing locals and visitors alike to a whole new reality.”
Sandbox VR’s UK and Ireland franchise partners, VR Entertainment Group, are proof of the strength of the Sandbox VR franchise program. Since launching their first store in London in July 2022—and their second in Birmingham a year later—they have surpassed the $10M revenue milestone. In London alone, VR Entertainment Group has seen a 16.8% increase in guests year-to-date and projects their 2024 revenue to top $5M.
“I believe our success is due to the strength of our partnership with Sandbox VR,” said Andy Scanlon, co-founder and CEO of VR Entertainment Group. “Their world class VR, brand, and wider corporate team, with our local expertise and determination to build Sandbox VR into the leading immersive entertainment brand in the UK & Ireland, has led to a nexus delivering truly amazing experiences for our guests.”
Sandbox VR is creating the future of entertainment by building the world’s most immersive experiences using proprietary virtual reality technology. Their patented motion-tracking system, which captures the movements of a player’s entire body, combines with high-quality haptics to provide players with unprecedented realism and complete immersion that’s not possible with home VR or other location-based VR platforms. Guests’ own bodies act as their game controllers; all they have to do is step into the virtual world and participate in the action unfolding all around them.
All Sandbox VR experiences—eight in total—are developed by in-house AAA gaming studios in Hong Kong and Vancouver, led by game industry veterans and are specifically designed for groups to play as social experiences. Teams of up to six freely roam and explore virtual worlds together, while relying on each other to succeed.
For more information and to make reservations, please visit sandboxvr.com. To learn more about Sandbox VR franchise opportunities, please visit https://franchise.sandboxvr.com/.
ABOUT SANDBOX VR
Sandbox VR is the world's premier destination for premium, location-based virtual reality games. The company has created the world’s most immersive full-body VR platform and boasts exclusive games, including original and branded experiences, such as Squid Game Virtuals, created in collaboration with Netflix. Now operating in 50 locations and attracting over 100k players monthly, Sandbox VR is rapidly growing its global footprint with thriving corporate-owned locations and a robust franchising program. The company has been recognized as one of Fast Company’s 2024 Most Innovative Companies and is the 129th fastest growing company in America on the 2024 Inc. 5000 list. Sandbox VR is headquartered in San Francisco, California with offices in Hong Kong and Vancouver. The company’s latest round raised over $37 million from investors including Andreessen Horowitz, Alibaba Entrepreneurs Fund, Gobi Partners, and Craft. Individual investors include Justin Timberlake, Katy Perry, Kevin Durant and Will Smith.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903348064/en/
Contacts
Dacyl Armendariz
Whipsmart Communications
sandboxvr@whipsmartpr.com
512.944.0944
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom